GPCR 241220 22.50C (GPCR241220C22500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

GPCR241220C22500

Watchlist

15.00
0.000.00%

15min DelayTrading Oct 15 11:51 ET

0.00High0.00Low

Intraday

5D
Daily

News

Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanksDec 9 10:30 ET · Ratings
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
Seeking AlphaDec 6 16:21 ET
Optimistic Outlook on Structure Therapeutics: Promising Drug Development Progress and Future Milestones
TipRanksDec 6 00:58 ET
Structure Therapeutics Price Target Raised to $91 From $86 at JMP Securities
TipRanksDec 5 06:40 ET
HC Wainwright & Co. Initiates Coverage On Structure Therapeutics With Buy Rating, Announces Price Target of $80
BenzingaDec 4 06:30 ET · Ratings
Structure Therapeutics Analyst Ratings
BenzingaDec 4 06:28 ET · Ratings

Comments

104266827

Sep 23 07:37

still uptrend..go buy target price $65

Share Your Profit/Loss

Jensen 108

Sep 13 11:34

this one so hard to achieve 10% above. profit taken first.

Share Your Profit/Loss

Jensen 108

Aug 13 09:44

$Structure Therapeutics (GPCR.US)$ hopefully the uptrend continues

Meltyy

Jul 17 22:40

Smid-cap obesity stocks hit by $RHHBY positive Ph1 data for oral GLP-1 obesity drug ⚠️

$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$

frankinglily

Jul 12 03:26

Is the diet pill market too profitable to lose?

Why do you think $Pfizer (PFE.US)$ decided to progress with Danuglipron? (Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA